Heart Disease Prevention Has a Surprising New Pillar

The shingles vaccine tends to sit near the bottom of the to-do list — recommended for every adult over 50, but rarely treated as urgent. It prevents a miserable rash, the thinking goes, so it can wait.

That calculus is changing. Over the past year, several large studies have converged on a surprising finding: older adults who get the shingles vaccine have meaningfully lower rates of heart attack and stroke. The effect is large enough that in 2025, the European Society of Cardiology — one of the most influential cardiology bodies in the world — formally called vaccination a new pillar of heart disease prevention.

What the studies found

Three findings stand out.

First, a nationwide study from South Korea, published in the European Heart Journal in 2025, followed more than a million people. Those who received the shingles vaccine had a 23% lower risk of cardiovascular events overall — and a 26% lower risk of major events like stroke, heart attack, or death from heart disease. The protection was strongest in the first two to three years but persisted for up to eight years. Notably, the benefit appeared even in people without known heart risk factors.

Second, a 2026 analysis presented through the American College of Cardiology examined more than 240,000 adults over 50 with existing atherosclerotic disease, drawn from a large U.S. health-records database — comparing those who received the shingles vaccine against an equal number of closely matched unvaccinated peers. Compared to unvaccinated peers, the vaccinated group was 32% less likely to have a heart attack and 25% less likely to have a stroke in the year after vaccination. One of the researchers noted that a reduction of that size is comparable to what you'd expect from quitting smoking.

Third, pulling the field together, a global systematic review and meta-analysis presented at the 2025 European Society of Cardiology Congress in Madrid found that shingles vaccination was associated with roughly a 16–18% reduction in cardiovascular events. In the studies that measured it, that translated to between one and two fewer cardiovascular events per 1,000 people each year.

Why would a skin-rash vaccine protect the heart?

The shingles virus — varicella-zoster virus — is the same virus that causes chickenpox. After a childhood infection, it never fully leaves the body. It goes dormant inside nerve cells for decades. As we age and our immune surveillance weakens, it can reactivate, traveling back down the nerves to the skin, where it produces the blistering, painful rash we call shingles.

But the virus doesn't only travel to the skin. It can also travel to the walls of arteries and infect them directly — something researchers have confirmed by finding the virus's genetic material and viral particles inside affected artery walls. That active infection triggers inflammation throughout the vessel wall, damages the delicate inner lining, thickens the vessel, and promotes the formation of blood clots. The result is a measurably higher risk of stroke and heart attack — a risk that stays elevated for weeks to months after a shingles episode, because the inflammation lingers.

In other words, shingles isn't just a skin disease. In a meaningful number of older adults, it's a vascular event waiting to happen. The vaccine works upstream of all of this — by preventing the reactivation in the first place, it heads off the infection and the clotting cascade that follows. That biological plausibility is a big part of why researchers and cardiologists are taking the association seriously rather than dismissing it as coincidence.

The ESC's new position

In 2025, the European Society of Cardiology published a clinical consensus statement titled Vaccination as a new form of cardiovascular prevention. Its central conclusion: vaccination should be considered a foundational pillar of cardiovascular prevention, alongside the three pillars clinicians have relied on for decades — blood pressure management, cholesterol management, and diabetes management.

The statement was not limited to shingles. It drew on evidence that a range of common infections — influenza, pneumococcal pneumonia, COVID-19, RSV — can destabilize existing heart disease and trigger cardiac events, and that the corresponding vaccines can reduce those complications, especially in people who already have cardiovascular disease.

It's worth being precise: a consensus statement is an expert review of the evidence, not a formal treatment guideline. But the direction is unmistakable, and it isn't only European. The 2025 American College of Cardiology/American Heart Association guidelines for acute coronary syndromes already give annual influenza vaccination a top-tier recommendation specifically for reducing major cardiovascular events.

Caveats

These studies show association, not proven cause. It's possible that people who get vaccinated are also more health-conscious in ways that independently lower their cardiovascular risk. The researchers did try to account for this — adjusting for factors like age, existing conditions, and lifestyle, and in the U.S. analysis comparing vaccinated people against closely matched unvaccinated peers — but no statistical adjustment can rule out every hidden difference. What strengthens the case is the combination of a consistent signal across multiple large, independent studies and a clear biological mechanism.

The bottom line

It's worth remembering why the shingles vaccine exists in the first place. Many people dismiss shingles as just a rash, but it can cause severe, long-lasting nerve pain and disability that lingers for months or even years after the rash clears. Preventing that remains the primary reason to get vaccinated. The emerging cardiovascular findings are simply another compelling reason to strongly consider it.

The vaccine is already recommended for every adult over 50. If you're in that group and haven't completed the two dose shingles vaccination, it's worth raising with your doctor at your next visit — particularly if you already have heart disease, diabetes, or other cardiovascular risk factors, the group that appears to benefit most. This is no longer a vaccine that belongs at the bottom of the list.